Shares of laser vision correction specialist LCA-Vision (LCAV) remain largely unchanged since the 4/25/13 release of LCA-Vision: The Case For Calculated Optimism. In the following overview, I will briefly recap the past six months and provide a progress reports to the LCAV long-term recovery thesis.
Q3 Earnings Highlights
- Revenues increased +3.2%. Procedure volume +3.7% to 11,932 in Q3. This is the first YOY volume increase in 5 quarters. YTD revenue of $71m and procedure volume of 41,198 remain depressed YOY due to tough 1H comps (FSA reductions). Q3 net loss of $1.6m, an improvement from a loss of $3.5m in 2012.
- Average revenue per procedure of $1,718, slightly higher than expected.
- Balance Sheet: Their financial
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: